161 related articles for article (PubMed ID: 38861914)
1. Unlocking the potential of tranilast: Targeting fibrotic signaling pathways for therapeutic benefit.
Massoud G; Parish M; Hazimeh D; Moukarzel P; Singh B; Cayton Vaught KC; Segars J; Islam MS
Int Immunopharmacol; 2024 Jun; 137():112423. PubMed ID: 38861914
[TBL] [Abstract][Full Text] [Related]
2. Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model.
Kelly DJ; Zhang Y; Gow R; Gilbert RE
J Am Soc Nephrol; 2004 Oct; 15(10):2619-29. PubMed ID: 15466266
[TBL] [Abstract][Full Text] [Related]
3. Keloids, hypertrophic scars, and uterine fibroid development: a prospective ultrasound study of Black and African American women.
Langton CR; Gerety M; Harmon QE; Baird DD
F S Sci; 2023 May; 4(2):172-180. PubMed ID: 37028513
[TBL] [Abstract][Full Text] [Related]
4. Tranilast Inhibits Pulmonary Fibrosis by Suppressing TGFβ/SMAD2 Pathway.
Kato M; Takahashi F; Sato T; Mitsuishi Y; Tajima K; Ihara H; Nurwidya F; Baskoro H; Murakami A; Kobayashi I; Hidayat M; Shimada N; Sasaki S; Mineki R; Fujimura T; Kumasaka T; Niwa SI; Takahashi K
Drug Des Devel Ther; 2020; 14():4593-4603. PubMed ID: 33149556
[TBL] [Abstract][Full Text] [Related]
5. Proteoglycans of uterine fibroids and keloid scars: similarity in their proteoglycan composition.
Carrino DA; Mesiano S; Barker NM; Hurd WW; Caplan AI
Biochem J; 2012 Apr; 443(2):361-8. PubMed ID: 22257180
[TBL] [Abstract][Full Text] [Related]
6. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis.
Uno M; Kurita S; Misu H; Ando H; Ota T; Matsuzawa-Nagata N; Kita Y; Nabemoto S; Akahori H; Zen Y; Nakanuma Y; Kaneko S; Takamura T
Hepatology; 2008 Jul; 48(1):109-18. PubMed ID: 18571789
[TBL] [Abstract][Full Text] [Related]
7. In vitro and vivo study of tranilast protects from acute respiratory distress syndrome and early pulmonary fibrosis induced by smoke inhalation.
Cui P; Tang Z; Zhan Q; Deng C; Lai Y; Zhu F; Xin H; Li R; Chen A; Tong Y
Burns; 2022 Jun; 48(4):880-895. PubMed ID: 35410697
[TBL] [Abstract][Full Text] [Related]
8. Interplay Between Keratinocytes and Fibroblasts: A Systematic Review Providing a New Angle for Understanding Skin Fibrotic Disorders.
Russo B; Brembilla NC; Chizzolini C
Front Immunol; 2020; 11():648. PubMed ID: 32477322
[No Abstract] [Full Text] [Related]
9. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta.
Martin J; Kelly DJ; Mifsud SA; Zhang Y; Cox AJ; See F; Krum H; Wilkinson-Berka J; Gilbert RE
Cardiovasc Res; 2005 Feb; 65(3):694-701. PubMed ID: 15664396
[TBL] [Abstract][Full Text] [Related]
10. Targeting fibrotic signaling pathways by EGCG as a therapeutic strategy for uterine fibroids.
Islam MS; Parish M; Brennan JT; Winer BL; Segars JH
Sci Rep; 2023 May; 13(1):8492. PubMed ID: 37231028
[TBL] [Abstract][Full Text] [Related]
11. Tranilast: a review of its therapeutic applications.
Darakhshan S; Pour AB
Pharmacol Res; 2015 Jan; 91():15-28. PubMed ID: 25447595
[TBL] [Abstract][Full Text] [Related]
12. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy.
Mifsud S; Kelly DJ; Qi W; Zhang Y; Pollock CA; Wilkinson-Berka JL; Gilbert RE
Nephron Physiol; 2003; 95(4):p83-91. PubMed ID: 14694265
[TBL] [Abstract][Full Text] [Related]
13. Role of Inflammasomes in Keloids and Hypertrophic Scars-Lessons Learned from Chronic Diabetic Wounds and Skin Fibrosis.
Huang C; Ogawa R
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743263
[TBL] [Abstract][Full Text] [Related]
14. Treatment of keloid and hypertrophic scars by iontophoretic transdermal delivery of tranilast.
Shigeki S; Murakami T; Yata N; Ikuta Y
Scand J Plast Reconstr Surg Hand Surg; 1997 Jun; 31(2):151-8. PubMed ID: 9232700
[TBL] [Abstract][Full Text] [Related]
15. A Review of the Evidence for and against a Role for Mast Cells in Cutaneous Scarring and Fibrosis.
Wilgus TA; Ud-Din S; Bayat A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33353063
[TBL] [Abstract][Full Text] [Related]
16. The Cellular Response of Keloids and Hypertrophic Scars to Botulinum Toxin A: A Comprehensive Literature Review.
Austin E; Koo E; Jagdeo J
Dermatol Surg; 2018 Feb; 44(2):149-157. PubMed ID: 29401161
[TBL] [Abstract][Full Text] [Related]
17. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts.
Suzawa H; Kikuchi S; Arai N; Koda A
Jpn J Pharmacol; 1992 Oct; 60(2):91-6. PubMed ID: 1282576
[TBL] [Abstract][Full Text] [Related]
18. Skin fibrosis associated with keloid, scleroderma and Jorge Lobo's disease (lacaziosis): An immuno-histochemical study.
Tafuri WL; Tomokane TY; Silva AMG; Kanashiro-Galo L; Mosser DM; Quaresma JAS; Pagliari C; Sotto MN
Int J Exp Pathol; 2022 Dec; 103(6):234-244. PubMed ID: 36183172
[TBL] [Abstract][Full Text] [Related]
19. Arctigenin suppresses fibroblast activity and extracellular matrix deposition in hypertrophic scarring by reducing inflammation and oxidative stress.
Jiang L; Deng Y; Li W; Lu Y
Mol Med Rep; 2020 Dec; 22(6):4783-4791. PubMed ID: 33174021
[TBL] [Abstract][Full Text] [Related]
20. Targeting fatty acid metabolism for fibrotic disorders.
Hwang S; Chung KW
Arch Pharm Res; 2021 Oct; 44(9-10):839-856. PubMed ID: 34664210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
